Tag: Janssen

Janssen Announced Positive Top-Line Results from Study of Cabotegravir

hiv
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced positive top-line results from the Phase 3 ATLAS-2M study of the investigational, long-acting two-drug injectable regimen o...

EU Approved Two New Imbruvica Uses

European regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of the blood cancer drug. Johnson & Johnson’s pharma unit said the Europea...

Alligator Bioscience Regained Exclusive Rights for CD40 from Janssen Biotech

Alligator Bioscience announced that it has regained exclusive, worldwide rights from Janssen Biotech Inc. to develop and commercialize the CD40 agonistic antibody, ADC-1013 (JNJ-64457107), its lead tu...

Janssen Announced Positive Results from the Study for Ponesimod

janssen
The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive top-line results from the Phase 3 OPTIMUM study, which evaluated the efficacy and safety of ponesimod compared to Aubag...

Janssen Announced Submission of Extension Application to EMA for DARZALEX®

janssen
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the skin) use of DARZA...

Celsius and Janssen in Collaboration

Celsius Therapeutics announced a collaboration with Janssen Biotech. Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify...

SMC Recommended Janssen’s Darzalex for Multiple Myeloma Treatment

The Scottish Medicines Consortium (SMC) has recommended Darzalex® (daratumumab) plus bortezomib and dexamethasone as an option for treating relapsed multiple myeloma in people who have had only one pr...

Genmab, Janssen Biotech Entered into Exclusive Worldwide License and Option Agreement

janssen
Genmab A/S announced it has entered into an exclusive worldwide license and option agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize HexaBody-CD38, a next-generation human CD...

J&J Published Data from Phase 3 DARZALEX® Study

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of data from the randomized, open-label Phase 3 MAIA (MMY3008) study that showed DARZALEX® (daratumumab) plus le...

Actelion Presented Latest Post-Hoc Analysis from the GRIPHON Study

janssen
Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has presented results of a post-hoc exploratory analysis of the GRIPHON study in patients with pulmo...

Janssen and Australian Institute Collaborate to Prevent PPH

Janssen Pharmaceutica N.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has entered into a sponsored research agreement with the Monash Institute of Pharmace...

FDA Approved Janssen Nasal Spray for Depression Treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved SPRAVATO™ (esketamine) CIII nasal spray for use in conjunction wi...

Janssen Got FDA Approval

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® One-Press, a single-dose, patient-controlled inject...

Morphic and Janssen in R&D Partnership

Morphic Therapeutic (Morphic), a biotechnology company developing oral integrin therapies, announced that it has entered into a research and development collaboration with Janssen Biotech, Inc. (Janss...

FDA Advisory Committee Voted For Janssen Depression Drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Manage...

Janssen and MeiraGTx to Work on Inherited Retinal Diseases

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc, a clinical-stage gene therapy company, to deve...